Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGENE-01: niraparib plus PD-1 inhibitor in HRR-mutated advanced solid tumors
jRCT2051210120Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of niraparib, nivolumab and pembrolizumab in transitional cell carcinoma (TCC), renal cell carcinoma (RCC), gastric cancer (GC) and 3 more (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Objective response rate. Started Apr 2022; status: active, not recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)renal cell carcinoma (RCC)gastric cancer (GC)esophageal cancerhead and neck cancer (HNC)
Beyond the preview
Go deeper on jRCT2051210120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210120.